tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI
US Market
DNLI
Denali Therapeutics
RESEARCH TOOLSreports
Want to see DNLI full AI Analyst Report?

Denali Therapeutics (DNLI) Stock Forecast & Price Target

886 Followers
See the Price Targets and Ratings of:

DNLI Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Denali
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DNLI Stock 12 Month Forecast

Average Price Target

$36.31
▲(57.11% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $36.31 with a high forecast of $42.00 and a low forecast of $26.00. The average price target represents a 57.11% change from the last price of $23.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","43":"$43","19.75":"$19.75","27.5":"$27.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.30769230769231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,19.75,27.5,35.25,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,24.48,25.939999999999998,27.4,28.86,30.32,31.78,33.239999999999995,34.7,36.16,37.62,39.08,40.54,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,24.042130177514792,25.064260355029585,26.086390532544378,27.10852071005917,28.130650887573964,29.152781065088757,30.17491124260355,31.197041420118342,32.219171597633135,33.24130177514793,34.26343195266272,35.28556213017751,{"y":36.30769230769231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,23.24923076923077,23.478461538461538,23.70769230769231,23.936923076923076,24.166153846153847,24.395384615384614,24.624615384615385,24.853846153846153,25.083076923076923,25.31230769230769,25.54153846153846,25.770769230769233,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.41,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$42.00Average Price Target$36.31Lowest Price Target$26.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on DNLI
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DNLI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$42
Buy
81.74%
Upside
Reiterated
08/07/26
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
Stifel Nicolaus Analyst forecast on DNLI
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$41
Buy
77.41%
Upside
Reiterated
08/07/26
Stifel Nicolaus Remains a Buy on Denali Therapeutics (DNLI)
Morgan Stanley Analyst forecast on DNLI
Sean Laaman
Morgan Stanley
Morgan Stanley
$36→$40
Buy
73.09%
Upside
Assigned
08/07/26
Morgan Stanley Sticks to Their Buy Rating for Denali Therapeutics (DNLI)
Bank of America Securities Analyst forecast on DNLI
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$31
Buy
34.14%
Upside
Reiterated
08/07/26
Denali Therapeutics (DNLI) Receives a Buy from Bank of America Securities
UBS Analyst forecast on DNLI
Michael Yee
UBS
UBS
$25→$34
Buy
47.12%
Upside
Assigned
08/07/26
Denali Therapeutics price target raised to $34 from $25 at UBSDenali Therapeutics price target raised to $34 from $25 at UBS
Robert W. Baird Analyst forecast on DNLI
Charles Moore
Robert W. Baird
Robert W. Baird
$31→$34
Buy
47.12%
Upside
Reiterated
08/07/26
Denali Therapeutics price target raised to $34 from $31 at BairdDenali Therapeutics price target raised to $34 from $31 at Baird
TD Cowen Analyst forecast on DNLI
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and SAB Biotherapeutics (NASDAQ: SABS)
BTIG Analyst forecast on DNLI
Thomas Shrader
BTIG
BTIG
$39
Buy
68.76%
Upside
Reiterated
08/06/26
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Goldman Sachs Analyst forecast on DNLI
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$41
Buy
77.41%
Upside
Reiterated
07/20/26
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)
Deutsche Bank Analyst forecast on DNLI
David Hoang
Deutsche Bank
Deutsche Bank
$31→$35
Buy
51.45%
Upside
Assigned
07/16/26
Denali Therapeutics price target raised to $35 from $31 at Deutsche BankDenali Therapeutics price target raised to $35 from $31 at Deutsche Bank
Jefferies Analyst forecast on DNLI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$40
Buy
73.09%
Upside
Reiterated
07/13/26
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Wedbush Analyst forecast on DNLI
Laura Chico
Wedbush
Wedbush
$20→$26
Buy
12.51%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)
J.P. Morgan Analyst forecast on DNLI
Jessica Fye
J.P. Morgan
J.P. Morgan
$29
Buy
25.49%
Upside
Initiated
07/13/26
Analysts Are Bullish on These Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Kardigan, Inc. (KARD)
Oppenheimer Analyst forecast on DNLI
Jay Olson
Oppenheimer
Oppenheimer
$35→$40
Buy
73.09%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Definitive Healthcare Corp (NASDAQ: DH) and Denali Therapeutics (NASDAQ: DNLI)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on DNLI
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DNLI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$42
Buy
81.74%
Upside
Reiterated
08/07/26
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
Stifel Nicolaus Analyst forecast on DNLI
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$41
Buy
77.41%
Upside
Reiterated
08/07/26
Stifel Nicolaus Remains a Buy on Denali Therapeutics (DNLI)
Morgan Stanley Analyst forecast on DNLI
Sean Laaman
Morgan Stanley
Morgan Stanley
$36→$40
Buy
73.09%
Upside
Assigned
08/07/26
Morgan Stanley Sticks to Their Buy Rating for Denali Therapeutics (DNLI)
Bank of America Securities Analyst forecast on DNLI
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$31
Buy
34.14%
Upside
Reiterated
08/07/26
Denali Therapeutics (DNLI) Receives a Buy from Bank of America Securities
UBS Analyst forecast on DNLI
Michael Yee
UBS
UBS
$25→$34
Buy
47.12%
Upside
Assigned
08/07/26
Denali Therapeutics price target raised to $34 from $25 at UBSDenali Therapeutics price target raised to $34 from $25 at UBS
Robert W. Baird Analyst forecast on DNLI
Charles Moore
Robert W. Baird
Robert W. Baird
$31→$34
Buy
47.12%
Upside
Reiterated
08/07/26
Denali Therapeutics price target raised to $34 from $31 at BairdDenali Therapeutics price target raised to $34 from $31 at Baird
TD Cowen Analyst forecast on DNLI
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and SAB Biotherapeutics (NASDAQ: SABS)
BTIG Analyst forecast on DNLI
Thomas Shrader
BTIG
BTIG
$39
Buy
68.76%
Upside
Reiterated
08/06/26
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Goldman Sachs Analyst forecast on DNLI
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$41
Buy
77.41%
Upside
Reiterated
07/20/26
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)
Deutsche Bank Analyst forecast on DNLI
David Hoang
Deutsche Bank
Deutsche Bank
$31→$35
Buy
51.45%
Upside
Assigned
07/16/26
Denali Therapeutics price target raised to $35 from $31 at Deutsche BankDenali Therapeutics price target raised to $35 from $31 at Deutsche Bank
Jefferies Analyst forecast on DNLI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$40
Buy
73.09%
Upside
Reiterated
07/13/26
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Wedbush Analyst forecast on DNLI
Laura Chico
Wedbush
Wedbush
$20→$26
Buy
12.51%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Krystal Biotech (NASDAQ: KRYS) and Denali Therapeutics (NASDAQ: DNLI)
J.P. Morgan Analyst forecast on DNLI
Jessica Fye
J.P. Morgan
J.P. Morgan
$29
Buy
25.49%
Upside
Initiated
07/13/26
Analysts Are Bullish on These Healthcare Stocks: Hinge Health, Inc. Class A (HNGE), Kardigan, Inc. (KARD)
Oppenheimer Analyst forecast on DNLI
Jay Olson
Oppenheimer
Oppenheimer
$35→$40
Buy
73.09%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Definitive Healthcare Corp (NASDAQ: DH) and Denali Therapeutics (NASDAQ: DNLI)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

3 Months
Michael YeeUBS
Success Rate
8/13 ratings generated profit
62%
Average Return
+4.50%
Copying Michael Yee's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +4.50% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
11/14 ratings generated profit
79%
Average Return
+19.16%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +19.16% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
12/14 ratings generated profit
86%
Average Return
+31.06%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +31.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNLI Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
22
25
13
16
10
Buy
10
10
6
9
9
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
35
19
25
19
In the current month, DNLI has received 19 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the past 3 months is 36.31.
Each month's total comprises the sum of three months' worth of ratings.

DNLI Financial Forecast

DNLI Earnings Forecast

Next quarter’s earnings estimate for DNLI is -$0.37 with a range of -$0.88 to $0.37. The previous quarter’s EPS was -$0.68. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.
Next quarter’s earnings estimate for DNLI is -$0.37 with a range of -$0.88 to $0.37. The previous quarter’s EPS was -$0.68. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Sales Forecast

Next quarter’s sales forecast for DNLI is $11.78M with a range of $3.00M to $35.80M. The previous quarter’s sales results were $3.60M. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.36% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.
Next quarter’s sales forecast for DNLI is $11.78M with a range of $3.00M to $35.80M. The previous quarter’s sales results were $3.60M. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.36% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Stock Forecast FAQ

What is DNLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 36.31.
    What is DNLI’s upside potential, based on the analysts’ average price target?
    Denali Therapeutics has 57.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DNLI a Buy, Sell or Hold?
          Denali Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Denali Therapeutics’s price target?
            The average price target for Denali Therapeutics is 36.31. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $42.00 ,the lowest forecast is $26.00. The average price target represents 57.11% Increase from the current price of $23.11.
              What do analysts say about Denali Therapeutics?
              Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of DNLI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.